BAAM
IMMU

Baker Avenue Asset Management’s Immunomedics Inc IMMU Stock Holding History

Baker Avenue Asset Management’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-12,751
Closed -$182K – 284
2018
Q4 		$182K Buy
+12,751
New +$253K 0.02% 237

Other funds holding IMMU

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Baker Avenue Asset Management's IMMU Position: Q1 2019 in Review

Baker Avenue Asset Management sold out of Immunomedics Inc (IMMU) in Q1 2019, closing a stake of 12,751 shares — an estimated $182K sold.

Baker Avenue Asset Management first reported a position in IMMU in Q4 2018 and held it in 1 quarter. The position peaked at $182K in Q4 2018. 204 funds tracked by Wall St. Rank hold IMMU as of Q1 2019.

  • Baker Avenue Asset Management reported no remaining Immunomedics Inc position as of Q1 2019 after selling out during the quarter.
  • Baker Avenue Asset Management sold 12,751 Immunomedics Inc shares in Q1 2019, an estimated $182K.
  • Baker Avenue Asset Management first reported a position in Immunomedics Inc in Q4 2018 and held it in 1 quarter.
  • Baker Avenue Asset Management's Immunomedics Inc position peaked at $182K in Q4 2018.
  • 204 funds tracked by Wall St. Rank held Immunomedics Inc as of Q1 2019.

Based on Baker Avenue Asset Management's 13F filing for Q1 2019, filed 15 May 2019.